newsfilter
← Earnings
Earnings Releases·

INVO Fertility — Third Quarter 2026 Earnings Summary

  • Total revenue increased 26% year-over-year to $2.22 million, driven by 28% growth in consolidated clinic revenue and full-quarter contributions from the Indiana and Birmingham acquisitions, while product revenue declined to $15,069 due to the elimination of sales to newly consolidated clinics.
  • Net loss narrowed to $2.1 million from $3.4 million in the prior-year quarter, with Clinic-Level Adjusted EBITDA remaining positive at $292,114 for the seventh consecutive quarter despite a $193,000 negative impact from the Birmingham clinic transition.
  • The balance sheet strengthened significantly with cash on hand rising to $3.7 million, current liabilities decreasing to $4.5 million from $10.3 million, and net equity increasing to $18.0 million ($15.09 per share).
  • Management expressed confidence in executing growth plans through organic expansion and continued acquisitions of independent practices, noting the strategic value of acquiring established clinics to increase scale while investing in infrastructure and personnel.
Company
INVO FERTILITY INC
Sector
Healthcare
Industry
Medical Devices